Reply to letter to the editor: Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder by Pitarokoili and Gold

Abstract

Get full access to this article

View all access options for this article.

References

Pitarokoili

Gold

Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder. Mult Scler J 2018; 24: 364–365.

Ishizu

Osoegawa

Mei

F-J

et al . Intrathecal activation of the IL-7/IL-8 axis in opticospinal multiple sclerosis. Brain 2005; 128: 988–1002.

Tanaka

Matsushita

Tateishi

et al . Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 2008; 71: 974–981.

Matsushita

Tateishi

Isobe

et al . Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS ONE 2013; 8(4): e61835.

Kira

Itoyama

Kikuchi

et al . Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12-months: Results of a phase 2 observational extension. BMC Neurol 2014; 14: 21.

Jander

Turowski

Kieseier

et al . Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler J 2012; 18: 1650–1652.

Visser

Wattjes

Pouwels

et al . Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 2012; 79: 2000–2003.

Comi

O’Connor

Montalban

et al . Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler J 2010; 16(2): 197–207.

Song

Yamasaki

Kawano

et al . Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. PLoS ONE 2014; 10(4): e0124923.

10.

Sato

Nakashima

Bar-Or

et al . Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. J Neuroimmunol 2014; 268(1–2): 95–98.